Frontera Therapeutics
Latest round
- Series B
Last raised
- Jul 2022
Total raised
- $195M
Investors
- 7
About Frontera Therapeutics
Based in Massachusetts, US, and founded in 2019, Frontera Therapeutics operates as a developer of gene therapy products. The company's founder and CEO, Yong Dai graduated from Peking University and he recently served as the Chief Technology Officer at Prevail Therapeutics. The company has an operation center in Shanghai and an R&D center in Boston. The company has developed an adeno-associated virus (AAV) gene expression system named APEX Technology & Manufacturing Platform. The platform includes validated AAV vectors, CMC processes, and early clinical data. The company also designs AAV gene therapy vectors to increase expression, enhance activity, and reduce immunogenicity. The company's pipelines include orphan diseases, ophthalmology, hematology, neuromuscular and metabolic diseases.
Who invested in Frontera Therapeutics
7 investors across 2 rounds
See all investors in Frontera Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Frontera Therapeutics
Who invested in Frontera Therapeutics?
Frontera Therapeutics has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Frontera Therapeutics raised?
Frontera Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Frontera Therapeutics last raise money?
Frontera Therapeutics's most recent round on record is a Series B, in Jul 2022.
What does Frontera Therapeutics do?
Based in Massachusetts, US, and founded in 2019, Frontera Therapeutics operates as a developer of gene therapy products.
Where is Frontera Therapeutics headquartered?
Frontera Therapeutics is headquartered in US.
Which VCs invest in companies like Frontera Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Frontera Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Frontera Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.